標的化ドラッグデリバリー市場：疾患タイプ別、用途別、エンドユーザー別、地域別

世界の標的化ドラッグデリバリー市場は、2025年には107億2,000万米ドルと推定され、2032年には308億8,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は16.3%で成長する見込みです。

図.標的化ドラッグデリバリー市場シェア（%）、2025年地域別

標的化ドラッグデリバリーとは、医薬化合物を体内の標的作用部位に直接送達することで、治療効果を最大化し、副作用を最小化することを指します。特定の細胞表面レセプターや抗原を認識するターゲティングリガンドや部位と薬剤のカプセル化やコンジュゲーションが含まれます。これにより、薬物キャリアシステムは体内の疾患細胞や組織を選択的に標的とすることができ、作用部位における薬物のバイオアベイラビリティを高め、全身的な副作用を軽減することができます。標的化ドラッグデリバリーは、薬剤の部位特異的な作用を可能にするため、がん、心血管疾患、神経疾患など、さまざまな慢性疾患の効果的な管理に大きな可能性を秘めています。

市場力学：

標的化ドラッグデリバリー市場は、主に慢性疾患の世界の有病率の上昇、優れた有効性と安全性プロファイルを備えた精密医薬品への需要の高まり、先進的なドラッグデリバリー技術に対する製薬企業の研究開発投資の増加によって牽引されています。さらに、慢性疾患に罹患しやすい高齢者人口の増加、ナノメディンと標的療法に関する進行中の調査、新規の標的薬剤製剤の規制承認などは、市場プレーヤーに有利な機会を創出する主な要因です。しかし、標的デリバリーシステムに関連する開発コストの高さ、新興国における臨床研究のための適切なインフラの欠如、標的薬剤製剤の複雑さは、急速な普及を抑制する主な課題です。手頃な価格で安定した標的送達ソリューションを開発するための業界専門家や研究者によるさまざまな取り組みが、今後数年間はこうした制約を克服するのに役立つと思われます。

本調査の主な特徴

• 本レポートでは、世界の標的化ドラッグデリバリー市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模（10億米ドル）と年間複合成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競合戦略などに関する重要な考察も提供しています。
• 世界の標的化ドラッグデリバリー市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界のドラッグデリバリー市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の標的化ドラッグデリバリー市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 主な発展
• 規制シナリオ
• メーカー収益
• 買収と提携のシナリオ
• 製品の発売/承認
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の標的化ドラッグデリバリー市場- コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の標的化ドラッグデリバリー市場、疾患タイプ別、2020年-2032年（10億米ドル）

• 心血管疾患
• 肺疾患
• 感染症
• 内分泌疾患
• 腫瘍性疾患

第6章 世界の標的化ドラッグデリバリー市場、用途別、2020年-2032年、（10億米ドル）

• 一次標的
• 二次標的
• 三次標的

第7章 世界の標的化ドラッグデリバリー市場、エンドユーザー別、2020年-2032年、（10億米ドル）

• 病院
• クリニック
• その他

第8章 世界の標的化ドラッグデリバリー市場、地域別、2020年-2032年、（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • AbbVie Inc.
  • Sanofi
  • Arrowhead Pharmaceuticals, Inc.
  • Baxter International Inc.
  • AstraZeneca
  • Boston Scientific Corporation
  • Depomed, Inc.
  • Fraunhofer Gesellschaft Munchen
  • Janssen Global Services, LLC
  • Luye Pharma Group
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • Savara Inc.
  • Roche Holding AG
  • Suda Limited
  • Taiwan Liposome Company, Ltd.
  • Vectura Group PLC

第10章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global Targeted Drug Delivery Market is estimated to be valued at USD 10.72 Bn in 2025 and is expected to reach USD 30.88 Bn by 2032, growing at a compound annual growth rate (CAGR) of 16.3% from 2025 to 2032.

Figure. Targeted Drug Delivery Market Share (%), By Region 2025

Targeted drug delivery refers to the delivery of pharmaceutical compounds directly to the targeted sites of action in the body, thus maximizing the therapeutic effects and minimizing the side effects. It involves the encapsulation or conjugation of drugs with targeting ligands or moieties that recognize specific cell-surface receptors or antigens. This allows the drug carrier system to selectively target the diseased cells or tissues in the body, thereby increasing the bioavailability of drugs at the site of action and reducing systemic side effects. Targeted drug delivery holds tremendous potential for the effective management of various chronic diseases like cancer, cardiovascular ailments, neurological disorders, etc. as it allows site-specific action of drugs.

Market Dynamics:

The targeted drug delivery market is primarily driven by the rising prevalence of chronic diseases globally, boosting the demand for precision medicines with superior efficacy and safety profiles, increasing R&D investments by pharmaceutical companies in advanced drug delivery technologies. Furthermore, the growing geriatric population susceptible to chronic health conditions, ongoing research on nanomedicines and targeted therapies, and regulatory approvals of novel targeted drug formulations are some key factors creating lucrative opportunities for market players. However, high development costs associated with targeted delivery systems, lack of proper infrastructure for clinical research in emerging nations, and complexity of targeted drug formulations are major challenges restraining the rapid adoption. Various initiatives by industry experts and researchers to develop affordable and stable targeted delivery solutions can help overcome these limitations in the coming years.

Key Features of the Study:

• This report provides an in-depth analysis of the global targeted drug delivery market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global targeted drug delivery market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes AbbVie Inc., Sanofi , Arrowhead Pharmaceuticals, Inc., Baxter International Inc., AstraZeneca , Boston Scientific Corporation, Depomed, Inc., Fraunhofer Gesellschaft Munchen, Janssen Global Services, LLC, Luye Pharma Group, Pfizer Inc., Quark Pharmaceuticals Inc., Rexahn Pharmaceuticals Inc., Savara Inc., Roche Holding AG, Suda Limited, Taiwan Liposome Company, Ltd., and Vectura Group PLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global targeted drug delivery market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global targeted drug delivery market.

Detailed Segmentation-

• By Disease Type:
  • Cardiovascular Diseases
  • Pulmonary Diseases
  • Infectious Diseases
  • Endocrine Diseases
  • Oncological Disorders
• By Application:
  • First Order Targeting
  • Second Order Targeting
  • Third Order Targeting
• By End User:
  • Hospitals
  • Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Sanofi
  • Arrowhead Pharmaceuticals, Inc.
  • Baxter International Inc.
  • AstraZeneca
  • Boston Scientific Corporation
  • Depomed, Inc.
  • Fraunhofer Gesellschaft Munchen
  • Janssen Global Services, LLC
  • Luye Pharma Group
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • Savara Inc.
  • Roche Holding AG
  • Suda Limited
  • Taiwan Liposome Company, Ltd.
  • Vectura Group PLC

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Targeted Drug Delivery Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Targeted Drug Delivery Market, By Disease Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Cardiovascular Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pulmonary Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Infectious Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Endocrine Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncological Disorders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Targeted Drug Delivery Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• First Order Targeting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Second Order Targeting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Third Order Targeting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Targeted Drug Delivery Market, By End User, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Targeted Drug Delivery Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AbbVie Inc.*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Arrowhead Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Baxter International Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Boston Scientific Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Depomed, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Fraunhofer Gesellschaft Munchen
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Janssen Global Services, LLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Luye Pharma Group
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • Savara Inc.
  • Roche Holding AG
  • Suda Limited
  • Taiwan Liposome Company, Ltd.
  • Vectura Group PLC

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact